2016-03-08T00:00:00.000-05:00
Q4 revenue growth,0.608835
reduced capital requirements,0.519006
core osmolarity business,0.322094
new model,0.472972
positive cash flow,0.322094
additional capital requirements,0.322094
forward-looking statements,-0.30563
significant P&L improvement,0.700975
Company,0.309527
continued growth,0.676144
TearLab Osmolarity Test,0.232458
TearLab,-0.0345062
